Skip to content

Study · Non-randomized trial · n = 48 · 2019

3 results

Effects of Weekly Teriparatide Administration for Vertebral Stability and Bony Union in Patients with Acute Osteoporotic Vertebral Fractures.

Kitaguchi K, Kashii M, Ebina K, Sasaki S, Tsukamoto Y, Yoshikawa H, Murase T

Asian spine journal19 Apr 2019Cited by 20 (Europe PMC)

PMID31000686 (opens in a new tab)PMCIDPMC6774000 (opens in a new tab)DOI10.31616/asj.2018.0311 (opens in a new tab)PepBankPUB-31000686
Read at sourcePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with acute osteoporotic vertebral fractures, teriparatide did not significantly reduce ΔVHa versus control.

    In plain wordsIn patients with vertebral fractures, teriparatide did not significantly improve vertebral stability compared with control.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeVertebral stability ΔVHa
    Study

    n = 48

    Comparator
    Activated vitamin D3 and calcium supplementation alone
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    56.5 μg once weekly · subcutaneous · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    Although not significant, ΔVHa, indicating vertebral stability, tended to be lower in the TPTD group at 12 weeks (p =0.17).
    2 context sentences
    Summary · context
    An open-label, non-randomized prospective study.
    Summary · context
    Forty-eight subjects with acute OVF were assigned to receive activated vitamin D3 and calcium supplementation or onceweekly subcutaneous injection of TPTD (56.5 μg) in combination with activated vitamin D3 and calcium supplementation for 12 weeks.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with severe osteoporosis, teriparatide reduced ΔVHa compared with control at 12 weeks.

    In plain wordsIn patients with severe osteoporosis, teriparatide improved vertebral stability compared with control at 12 weeks.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseVertebral stability in severe osteoporosis
    Study

    n = 31

    Comparator
    Activated vitamin D3 and calcium supplementation alone
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    56.5 μg once weekly · subcutaneous · 12 weeksAs given in this study (human).

    Measurements

    Mean ΔVHa
    3.1 mm
    severe osteoporosis, control group, 12 weeks
    Mean ΔVHa
    1.4 mm
    severe osteoporosis, teriparatide group, 12 weeks

    Source sentences

    Summary
    As for subjects with severe osteoporosis, ΔVHa at 12 weeks was significantly lower in the TPTD group than in the control group (mean ΔVHa: control group, 3.1 mm (n=15); TPTD group, 1.4 mm (n=16); p =0.02).
    2 context sentences
    Summary · context
    An open-label, non-randomized prospective study.
    Summary · context
    Forty-eight subjects with acute OVF were assigned to receive activated vitamin D3 and calcium supplementation or onceweekly subcutaneous injection of TPTD (56.5 μg) in combination with activated vitamin D3 and calcium supplementation for 12 weeks.
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with acute vertebral fractures and severe osteoporosis, teriparatide increased bony union compared with vitamin D3 and calcium alone.

    In plain wordsIn patients with vertebral fractures and severe osteoporosis, teriparatide increased bone union compared with vitamin D3 and calcium alone.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseBony union rate
    Study

    n: not reported in source

    Comparator
    Activated vitamin D3 and calcium supplementation alone
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    56.5 μg once weekly · subcutaneous · 12 weeksAs given in this study (human).

    Measurements

    Bony union rate
    40%
    control group
    Bony union rate
    81%
    teriparatide group

    Source sentences

    Summary
    The rate of bony union was significantly higher in the TPTD group than in the control group (control group, 40%; TPTD group, 81%; p =0.03).
    2 context sentences
    Summary · context
    An open-label, non-randomized prospective study.
    Summary · context
    Forty-eight subjects with acute OVF were assigned to receive activated vitamin D3 and calcium supplementation or onceweekly subcutaneous injection of TPTD (56.5 μg) in combination with activated vitamin D3 and calcium supplementation for 12 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.